T
The Retina Group of Washington | Fairfax, Virginia
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
Pegcetacoplan
bevacizumab
APL-2
EYP-1901
ranibizumab
zeaxanthin
DHA
EPA
Parent organization
This site is a part of The Retina Group of Washington
Curious how this site stacks up to its peers?
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
2 of 10 total trials
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Enrolling
Wet Age Related Macular Degeneration
wAMD
Drug: Aflibercept (2.0 mg)
Drug: EYP-1901
This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...
Active, not recruiting
Geographic Atrophy Secondary to Age-related Macular Degeneration
Drug: PEGCETACOPLAN (APL-2)
Trial sponsors
A
A
E
T
Clinical trials
Research sites
Resources
Legal
© Copyright 2025 Veeva Systems